Identification of patients with non-D, non-C irritable bowel syndrome and treatment with renzapride: An exploratory, multicenter, randomized, double-blind, placebo-controlled clinical trial

Digestive Diseases and Sciences

Volumn 53, Issue 12, 2008, Pages 3191-3200

  Spiller, R C ^a   Meyers, N L ^b   Hickling, R I ^b  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b Alizyme plc   (United Kingdom)

Author keywords

5 HT4 5 HT3; Clinical trial; IBS; Non C; Non D; Patients; Renzapride

Indexed keywords

PLACEBO; RENZAPRIDE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIARRHEA PREDOMINANT IRRITABLE BOWEL SYNDROME; DIVERTICULITIS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; ECG ABNORMALITY; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; HEADACHE; HEART ARRHYTHMIA; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PATIENT IDENTIFICATION; PATIENT SAFETY; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADULT; BENZAMIDES; BICYCLO COMPOUNDS, HETEROCYCLIC; DEFECATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; RECEPTORS, SEROTONIN, 5-HT3; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 55949095879     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-008-0295-x     Document Type: Article

References (25)

1. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA (2000) Functional bowel disorders and functional abdominal pain. In: Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE (eds) Rome II. The functional gastrointestinal disorders. Diagnosis, pathophysiology and treatment: a multinational consensus, 2nd edn. Degnon Associates, McLean, VA, pp 351-432
2. GF Longstreth GT Thompson WD Chey LA Houghton F Mearin RC Spiller 2006 Functional bowel disorders Gastroenterology 130 1480 1491
3. M Simren H Abrahamsson J Svedlund ES Bjornsson 2001 Quality of life in patients with irritable bowel syndrome seen in referral centers vs. primary care: the impact of gender and predominant bowel pattern Scand J Gastroenterol 36 545 552
4. F Mearin A Balboa X Badia E Baro E Caldwell M Cucala M Diaz-Rubio A Fueyo J Ponce M Roset NJ Talley 2003 Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype Eur J Gastroenterol Hepatol 15 165 172
5. AP Hungin PJ Whorwell J Tack F Mearin 2003 The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects Aliment Pharmacol Ther 17 643 650
6. 4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation Aliment Pharmacol Ther 15 1655 1666
7. M Camilleri WY Chey EA Mayer AR Northcutt A Heath GE Dukes D McSorley AM Mangel 2001 A randomized controlled clinical trial of the serotonin type-3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome Arch Intern Med 161 1733 1740
8. A Dumuis M Sebben J Bockaert 1989 BRL 24924: a potent agonist at a non-classical 5-HT receptor positively coupled with adenylate cyclase in colliculi neurons Eur J Pharmacol 162 381 384
9. MR Briejer LMA Akkermans JAJ Schuurkes 1995 Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility Pharmacol Rev 47 631 651
10. J Tack S Muller-Lissner P Bytzer R Corinaldesi L Chang A Viegas S Schnekenbuehl C Dunger-Baldauf P Rueegg 2005 A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation Gut 54 1707 1713
11. J Tack SJ Middleton MC Horne H Piessevaux JS Bloor NL Meyers RMJ Palmer 2006 Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome Aliment Pharmacol Ther 23 1655 1665
12. M Camilleri S McKinzie J Fox A Foxx-Orenstein D Burton G Thomforde K Baxter AR Zinsmeister 2004 Effect of renzapride on transit in constipation-predominant irritable bowel syndrome Clin Gastroenterol Hepatol 2 895 904
13. 3 receptor antagonist, slows colonic transit in healthy man Dig Dis Sci 35 477 480
14. 3 mediation of human gastrocolonic response and colonic peristaltic reflex Am J Physiol 275 G498 G505
15. MD Gunput 1999 Clinical pharmacology of alosetron Aliment Pharmacol Ther 13 Suppl 2 70 76
16. M Delvaux D Louvel JP Mamet R Campos-Oriola J Frexinos 1998 Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome Aliment Pharmacol Ther 12 849 855
17. 3 receptor antagonist Dig Dis Sci 44 20 24
18. 3-receptor antagonist in patients with irritable bowel syndrome Aliment Pharmacol Ther 7 175 180
19. 3 receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetized rat Gut 46 474 480
20. SM Patel WB Stason A Legedza SM Ock TJ Kaptchuk L Conboy K Canenguez JK Park E Kelly E Jacobson CE Kerr AJ Lembo 2005 The placebo effect in irritable bowel syndrome trials: a meta-analysis Neurogastroenterol Motil 17 332 340
21. BD Naliboff S Berman L Chang SW Derbyshire B Suyenobu BA Vogt M Mandelkern EA Mayer 2003 Sex-related differences in IBS patients: central processing of visceral stimuli Gastroenterology 124 1738 1747
22. KM Koch JL Palmer N Noordin JJ Tomlinson C Baidoo 2002 Sex and age differences in the pharmacokinetics of alosetron Br J Clin Pharmacol 53 238 242
23. 3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome Neurogastroenterol Motil 17 212 221
24. K Tillisch JS Labus BD Naliboff R Bolus M Shetzline EA Mayer L Chang 2005 Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome Am J Gastroenterol 100 896 904
25. Kamm MA (2002) Pharmacological treatment of irritable bowel syndrome - from concept to sales. Eur J Surg Suppl (587):10-15